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Abstract
Background: Continuous renal replacement therapy (CRRT) is an excellent method used to remove fluid and solutes. It may
also reduce the systemic inflammatory response for patients on extracorporeal membrane oxygenation (ECMO) support. The
objective of this report is to describe a case where CRRT in combination with ECMO was insufficient to control hyperkalemia.
Methods: We report the case of an adolescent patient with refractory symptomatic hyperkalemia due to substantial
rhabdomyolysis in which CRRT insufficiently cleared the patient’s excess potassium.
Results: Intermittent hemodialysis (IHD) was added and proved successful. The patient was weaned off ECMO, CRRT, and
IHD, and his cardiac and renal function eventually normalized.
Conclusions: Two important lessons can be learned from this case report: (1) If CRRT is insufficient in achieving a desirable
potassium balance, additional IHD should be considered and (2) separate IHD access should be considered to improve
efficacy.
Abrégé
Contexte : La thérapie de remplacement rénal continue (TRRC) est une procédure très efficace pour éliminer les solutés
et les fluides. Elle peut également contribuer à la diminution de la réponse inflammatoire systémique chez les patients sous
oxygénation extracorporelle par membrane (technique ECMO). Ce rapport décrit un cas où la TRRC, en combinaison avec
l’ECMO, s’est avérée insuffisante pour réguler l’hyperkaliémie.
Méthodologie : Nous rapportons le cas d’un patient adolescent présentant une hyperkaliémie symptomatique réfractaire
due à une rhabdomyolyse substantielle chez qui la TRRC s’est avérée insuffisante pour éliminer l’excédent de potassium.
Résultats : Chez ce patient, l’ajout de l’hémodialyse intermittente s’est avéré un succès. On a par la suite cessé les traitements
(TRRC, EMCO et hémodialyse intermittente) et les fonctions cardiaque et rénale du patient sont revenues à la normale.
Conclusions : Ce rapport de cas nous permet de tirer deux conclusions importantes. D’abord, qu’il convient d’envisager l’ajout
d’un traitement par hémodialyse intermittente dans les cas où la TRRC est insuffisante pour assurer l’équilibre du potassium.
Ensuite, que pour améliorer l’efficacité de l’hémodialyse intermittente, il est important de lui assurer un accès indépendant.
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What was known before
While continuous renal replacement therapy (CRRT) is the
default renal replacement method in patients with acute kidney injury (AKI) and extracorporeal membrane oxygenation
(ECMO), the clearance of potassium and other small solutes
is superior on hemodialysis.

What this adds
Consultation with a nephrologist can assist the intensivist
with the choice of the best method for renal replacement
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Figure 1. Etiology and management of hyperkalemia.

Note. ECMO = extracorporeal membrane oxygenation; CVVHDF = continuous venovenous hemodiafiltration.

therapy, specific to the therapeutic goal. CRRT may not
always compensate for multiple sources of endogenous
potassium and thus may not adequately clear potassium.

Introduction
Acute kidney injury (AKI) is very common in patients placed
on extracorporeal membrane oxygenation (ECMO) for cardiac failure.1,2 This result is multifactorial: hypoperfusion
from a low cardiac output, nonpulsatile renal blood flow in
venoarterial-ECMO (VA-ECMO), ischemia/reperfusion
injury, systemic inflammatory response syndrome, and
hemolysis.3-5 AKI can also have direct negative effects on the
heart.6 The etiology of the resulting cardiac damage is also
multifactorial and includes systemic inflammatory response
syndrome with increased vascular permeability, electrolyte
disturbances, acidosis, and uremia. These influences lead
to a poor prognosis for patients on VA-ECMO for cardiac
failure who develop AKI.2,7-12
Accordingly, initiating continuous renal replacement therapy (CRRT) early in patients on ECMO may be beneficial as
it ameliorates the impact of AKI as shown by Antonucci
et al.13 CRRT is excellent for removing fluid and solutes and
may reduce the systemic inflammatory response.14

Methods
We present the case of an adolescent who underwent cardiogenic shock and required VA-ECMO. He developed refractory hyperkalemia and worsening azotemia from multiple
causes despite early initiation and optimization of CRRT.
Adding intermittent hemodialysis (IHD) successfully led to
an improvement in the patient’s hyperkalemia and azotemia.
There are little data describing the addition of IHD to continuous venovenous hemodiafiltration (CVVHDF) for a
patient on VA-ECMO, especially in pediatrics. Informed
consent for this report was obtained both from the patient
and from his parents.

Results
A 17-year-old male (47 kg) with a history of Crohn disease
presented to our hospital in cardiogenic shock. He was
treated with broad-spectrum antibiotics for septic shock and
was aggressively supported with fluid boluses, inotropes,
vasoactives, and steroids. He also developed a pericardial
effusion that required the percutaneous drainage of 150 mL
of serous fluid. Within a few hours of admission and despite
these interventions, he progressed to cardiac standstill and
required extracorporeal cardiopulmonary resuscitation, that
is, he was cannulated to a VA-ECMO circuit while cardiopulmonary resuscitation was performed.
Within 24 hours of ECMO cannulation, the patient developed hyperkalemia. The etiology of the hyperkalemia was
thought to be multifactorial. The patient had significant
hemolysis, rhabdomyolysis, and AKI. The hyperkalemia (8.2
mmol/L) was refractory despite the administration of lowdose dopamine, encouraging urine output with diuretics,
optimizing ECMO circuit flows to minimize hemolysis, minimizing nephrotoxic medications, and giving medications for
hyperkalemia (sodium bicarbonate, diuretics, insulin and dextrose, and salbutamol, all within a 6-hour window) (Figure 1).
The hyperkalemia produced a wide Q wave, R wave, and S
wave (QRS) complex (despite the administration of calcium
infusions and normal ionized calcium values on point-of-care
testing), and the patient developed anuria. His laboratory
results at the time were as follows: urea 12.9 mmol/L (normal
≤8.3), creatinine 234 µmol/L (normal = 62-120), phosphate
2.73 mmol/L (normal = 0.8-1.33), creatine kinase >25 300
U/L (normal ≤190), haptoglobin <0.7 g/L (normal = 0.2-2.26),
total bilirubin 21.3 µmol/L (normal = 3.4-17.1) and direct bilirubin 6.9 µmol/L (normal = 0-5), lactate dehydrogenase 1219
U/L (normal ≤225), and lactate 7.9 mmol/L (normal ≤2.4).
We introduced CVVHDF to the ECMO circuit proximal
to the oxygenator using the Prismaflex system (Figure 2).
The CRRT circuit was connected in parallel to avoid high
access pressures, with the outflow line originating from the
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Figure 2. Circuit setup.

Note. CVVHDF = continuous venovenous hemodiafiltration; IHD =
intermittent hemodialysis; ECMO = extracorporeal membrane oxygenation.

patient’s venous line and the inflow line attached to the
patient’s arterial cannula before the oxygenator. Nonetheless,
high access pressures from the ECMO circuit limited the
blood flow rate, so it was set at 150 mL/min. The pre-blood
pump (PBP) was set to 1000 mL/h, which is the rate given on
standard preprinted orders. The dialysate (PrismaSol 0) rate
was set to 1000 mL/h, which is also the rate on standard preprinted orders, and increased to 6000 mL/h, while the postfilter replacement (PrismaSol 0) rate was set to 1000 mL/h. The
Prismaflex has broad flow rate capabilities for blood flows,
dialysate, and replacement rates and can deliver up to 8000
mL/h of dialysate (replacement plus PBP). Potassium levels
did not improve, so we elected to add IHD to improve the
potassium balance (Figure 2). An additional central venous
line was inserted for this purpose. His IHD treatment duration was 4 hours, with a dialysate flow rate of 800 mL/min
(normal dialysate flow for maintenance dialysis 500 mL/
min) and a maximal blood flow rate of 300 mL/min (normal
pediatric blood flow rate 4-8 mL/kg/min for maintenance
dialysis). The maximum blood flow rate that the dialysis
machine that we used could produce was 300 mL/min. The
dialyzer employed an F200NR filter to achieve maximum
clearance. There was no potassium in the dialysate. We were
successful in reducing potassium levels (Figure 3), and the
ECG changes normalized with the additional hemodialysis.
After normalization of the hyperkalemia, the patient’s
CVVHDF was discontinued after 4.5 days and switched to
continuous venovenous hemodialysis (CVVHD). The patient
was weaned off ECMO after 1 week, came off CVVHD after
13 days, and continued IHD 3 to 4 times per week for a total
of 7 weeks until the AKI improved. His cystatin C estimated
glomerular filtration rate (eGFR)15 was 23 (normal ≥ 91) 3
weeks after presentation and is now (6 months later) only
mildly impaired at 71 mL/min/1.73 m2(chronic kidney disease [CKD] stage II, normal eGFR at this age 90-135 mL/
min/1.73 m2). His urea and creatinine normalized within
3 months of presentation and have remained normal.

Discussion
The concomitant use of CRRT and ECMO is common. In
one case series, 71% of pediatric cardiac patients on ECMO

Figure 3. Serum potassium in the week following admission.

Note. The patient only remained normokalemic on CRRT for a few
hours. “Renal dose” dopamine was then started, ventolin was given,
nephrotoxic drugs were discontinued, sodium bicarbonate was given via
IV, and high doses of furosemide (3 mg/kg in repeated boluses), insulin,
and dextrose were administered. As these initiatives were unsuccessful,
the dialysis rate of the Prismaflex machine was increased to 6.0 L/h for a
total flow rate of 8000 mL/h (dialysate, replacement plus PBP) until day
4 of the CRRT treatment. As none of these concurrent measures were
able to lower the patient’s potassium level, additional IHD was started
with 4-hour treatment cycles interrupted by an 8-hour break; the second
treatment caused hypokalemia, so the treatment was stopped. CVVHDF
was discontinued after 4.5 days. The patient then received CVVHD until
day 13 and was then continued on IHD for a total of 7 weeks, until the
AKI resolved. IV = intravenous; CRRT = continuous renal replacement
therapy; ECMO = extracorporeal membrane oxygenation; CVVHDF
= continuous venovenous hemodiafiltration; CVVHD = continuous
venovenous hemodialysis; PBP = pre-blood pump; IHD = intermittent
hemodialysis; AKI = acute kidney injury.

suffered AKI.2 Of 155 pediatric patients cannulated onto
VA-ECMO for heart failure secondary to myocarditis, 42
(27%) patients required dialysis.12 In a large series of pediatric patients who required ECMO for a variety of indications,
144 (41%) required CRRT.16 CRRT is typically sufficient
for managing fluid overload, acidosis, and electrolyte disturbances. We present a case where CRRT (in this case
CVVHDF) was not sufficient in managing severe refractory
hyperkalemia despite maximal settings on CVVHDF and
ongoing medical management of the hyperkalemia. While
we cannot ascertain beyond a doubt that IHD really had to be
introduced, the intensivist felt that medical treatment was
exhausted and that a higher blood flow (the treatment was
already at maximum with 8 L/h) was unacceptable because
of the high access pressures. High access pressures on
CVVHDF connected to an ECMO circuit are a documented
complication.17 The refractory hyperkalemia was likely due
to the patient’s continuing massive rhabdomyolysis in addition to hemolysis secondary to ECMO. The addition of IHD
rapidly reduced potassium levels in a case of severe ongoing
rhabdomyolysis.
It is important for a clinician to consider high-dose CRRT
in patients like this when AKI develops, and if this fails, adding IHD to CRRT or replacing CRRT with IHD if a patient

4
exhibits refractory AKI and persistent hyperkalemia while on
ECMO. Early involvement of the nephrology service may
have further expedited this process. In our case, the potassium
generation exceeded the potassium removal with the maximum treatment delivery of 8 L on CRRT, which is the main
reason why IHD was added. In addition to the negative effects
of AKI on cardiac function discussed in the “Introduction”
section, it is important to reduce severe and persistent hyperkalemia because of its arrhythmogenicity. There is evidence
of increased mortality in pediatric patients with cardiac
arrhythmias while on ECMO.12 Our patient’s QRS complex
widening on ECG resolved with the initiation of IHD.
A good functioning vascular access is an essential component for adequate renal replacement therapy for AKI. We
used the existing ECMO access for the CRRT in parallel
rather than in series, due to the well-described high access
pressures that may be associated with having all blood passing through both ECMO and CRRT in a sequential setup.17
The parallel setup may, however, have limited the potassium
clearance as not all the blood going through the ECMO circuit would be processed by the CRRT.18 To maximize the
efficacy of IHD, we elected to utilize the right jugular vein
for separate IHD access as this is the preferred insertion site
for a temporary dialysis catheter.18 We hypothesize that this
was an important component of our successful treatment,
although we cannot prove that CRRT through separate access
might have been more efficient than our chosen setup in
removing the potassium. Indeed, the dialysis prescription of
the CVVHDF was low, and perhaps the refractory hyperkalemia could have been avoided with had a much higher prescription been introduced earlier.
In the latest Extracorporeal Life Support Organization
(ELSO) report, between 35% and 52% of pediatric patients
who required ECMO for cardiogenic shock survived to
discharge or transfer.19 The survival rate was lower in those
who underwent extracorporeal cardiopulmonary resuscitation
(E-CPR) and further decreased in those who developed acute
renal failure.2,12,16,20 Our patient would have had ongoing
cardiac insult, undesirable potassium levels despite the use
of CRRT, and a lower likelihood of recovery if we had not
aggressively added IHD to correct the potassium imbalance.
Of course, IHD could have been chosen instead of CRRT, but
this has the disadvantage of discontinuous fluid removal. Still,
adding IHD can pose some risks. Large fluid shifts in intermittent dialysis can create hemodynamic instability, and there is a
risk of catastrophic bleed when inserting a central access line
in an anticoagulated patient. We considered using peritoneal
dialysis, but it is not as effective as IHD for clearing solutes.

Conclusion
To conclude, CRRT may not always compensate for multiple
sources of endogenous potassium and thus may not adequately clear potassium. We present the unique case of an
adolescent on VA-ECMO for cardiogenic shock who survived and regained full renal and cardiac function after IHD
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was added to CRRT to manage his persistent refractory
hyperkalemia. There are 2 important teachable moments:
First, in consultation with a nephrologist, consider adding an
additional renal replacement modality if the balance of any
uremic toxin remains unfavorable despite optimizing CRRT.
Given that potassium is best cleared by conventional hemodialysis, our choice was IHD. Second, consider separate vascular access to maximize the efficacy of the additional renal
replacement therapy.
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